A novel point-of-care device for measuring glucose-6-phosphate dehydrogenase enzyme deficiency.

Abstract

Extreme hyperbilirubinemia can cause bilirubin neurotoxicity. Infants with glucose-6-phosphate dehydrogenase (G6PD) deficiency can develop hemolysis and thus are at high risk. We evaluated a device that quantitatively measures G6PD activity kinetically using digital microfluidics (DMF). Intra- and inter-instrument and -day imprecision (CVs) were first assessed. G6PD activity in 86 samples was then measured and compared between DMF and 2 reference methods. Overall DMF reproducibility was 3.8% over 5 days by 2 operators on 2 instruments. Mean intra- and inter-instrument variabilities were 3.6% and 3.9%, respectively (n = 28), with a user variability of 4.3%. Mean G6PD activity was 6.40±4.62 and 6.37±4.62 U/g hemoglobin for DMF and Reference Methods 1 (n = 46) and 12.15±3.86 and 11.48±1.55 for DMF and 2 (n = 40), respectively, and strongly correlated (r = 0.95 and 0.95) with mean biases of +0.04±2.90 and +0.67±1.55 for methods 1 and 2, respectively. The novel device could be used for early newborn G6PD screening.

• Authors: Ronald J Wong, Cynthia Montiel, Megana Kunda, David K Stevenson, Vinod K Bhutani
• Journal: Seminars in perinatology (Semin Perinatol) Vol. 45 Issue 1 Pg. 151356 (02 2021) ISSN: 1558-075X [Electronic] United States
• PMID: 33293060 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Chemical References

• Glucosephosphate Dehydrogenase
• Bilirubin

Topics

• Bilirubin
• Glucosephosphate Dehydrogenase (analysis)
• Glucosephosphate Dehydrogenase Deficiency (diagnosis)
• Humans
• Infant
• Infant, Newborn
• Point-of-Care Systems
• Reproducibility of Results